Gesellschaftsrecht / M&A

Steuern

Vectivio

On August 31, 2021, VectivBio Holding AG announced the acquisition of Comet Therapeutics, Inc., a biotechnology company that has been developing drugs to address previously untreatable inherited metabolic diseases. This acquisition significantly expands VectivBio&#8217;s rare disease pipeline.
VectivBio will acquire Comet Therapeutics in exchange for equity and cash payable at closing, as well as additional equity or cash payments upon the achievement of future development milestones. The transaction is expected to close by the end of September 2021, subject to customary closing conditions.
Homburger advises VectivBio Holding AG in this matter. The Homburger team includes partner Andreas Müller, associates Margrit Marti, Angela Oppliger and Kevin Hubacher (all Corporate / M&amp;A), partner Stefan Oesterhelt and associate Joël Gyger (both Tax).

Homburger advises VectivBio on its acquisition of Comet Therapeutics

Arbeitsrecht und Vergütung für Führungskräfte

Kapitalmarkt

IP / IT

On April 9, 2021, VectivBio Holding AG announced its initial public offering and listing of its shares on Nasdaq (ticker symbol VECT). VectivBio is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Through its IPO, at USD 17 per share, VectivBio raises gross proceeds of USD 146.6 m (including greenshoe). At market close on the first day of trading, VectivBio had a market capitalization of USD 824 m.
Homburger advises VectivBio Holding AG in this matter. The Homburger team includes partner Andreas Müller (Capital Markets; Corporate / M&amp;A; Employment and Executive Compensation), lead associate Margrit Marti, associates Angela Oppliger and Kevin Hubacher and junior associate Daniel Bötticher (all Capital Markets; Corporate / M&amp;A), partner Stefan Oesterhelt and associates Joël Gyger and Raphaël Fellay (all Tax), and partner Luca Dal Molin (IP/IT).

Homburger advises VectivBio on its IPO on Nasdaq

On October 15, 2020, VectivBio AG, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, announced that it has closed a USD 110 m crossover financing from new investors Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset Management, with participation from existing investors Versant Ventures, OrbiMed, Novo Holdings, BPI France, Tekla Healthcare Investors, Inserm Transfert Initiative and Cowen Healthcare Investments.
Proceeds from the financing will be used to support the further clinical development of VectivBio&#8217;s lead investigational product, apraglutide, to treat short bowel syndrome (SBS), early commercialization activities and further development of the pipeline through business development initiatives.
The Homburger team was led by partner Andreas Müller and included lead associate Margrit Marti, associates Angela Oppliger and Mirko Stiefel and transaction and corporate support specialist Carolina Rodriguez (all Corporate / M&amp;A), partner Luca Dal Molin and associate Kirsten Schmidt (both IP / IT) as well as partner Stefan Oesterhelt and associates Joël Gyger and Raphaël Fellay (all Tax).

Joël
Gyger

Homburger advises VectivBio on its acquisition of Comet Therapeutics

Homburger advises VectivBio on its IPO on Nasdaq

Homburger advises VectivBio on USD 110 m Crossover Financing

Join the Team

Joël Gyger

Karriere

Sprachen

Zulassung

Teams

JoëlGyger

Homburger advises VectivBio on its acquisition of Comet Therapeutics

Homburger advises VectivBio on its IPO on Nasdaq

Homburger advises VectivBio on USD 110 m Crossover Financing

Join the Team

Joël Gyger

Karriere

Sprachen

Zulassung

Teams

Joël
Gyger